|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.050 AUD | 0.00% |
|
-2.84% | -24.63% |
| 03-12 | Mesoblast Limited Appoints Dr. Teresa Montagut As Head Of Clinical Development And Medical Affairs | CI |
| 03-11 | Mesoblast Appoints Head of Clinical Development, Medical Affairs | MT |
| Fiscal Period: June | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -9.22 | -7.16 | -6.5 | -5.41 | -5.37 | |||||
Return on Total Capital | -10.21 | -7.8 | -7.09 | -5.95 | -5.89 | |||||
Return On Equity % | -17.48 | -16.94 | -16.4 | -17.91 | -18.95 | |||||
Return on Common Equity | -17.48 | -16.94 | -16.4 | -17.91 | -18.95 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | -1.05K | -522.58 | -632.2 | -595.87 | -132.22 | |||||
SG&A Margin | 413.99 | 266.48 | 338.27 | 400.3 | 228.57 | |||||
EBITDA Margin % | -1.43K | -763.01 | -891.12 | -950.14 | -338.31 | |||||
EBITA Margin % | -1.44K | -774.21 | -903.83 | -957.08 | -340.06 | |||||
EBIT Margin % | -1.46K | -789.09 | -923.73 | -982.24 | -363.08 | |||||
Income From Continuing Operations Margin % | -1.33K | -894.59 | -1.09K | -1.49K | -593.92 | |||||
Net Income Margin % | -1.33K | -894.59 | -1.09K | -1.49K | -593.92 | |||||
Net Avail. For Common Margin % | -1.33K | -894.59 | -1.09K | -1.49K | -593.92 | |||||
Normalized Net Income Margin | -991.79 | -566.17 | -757.8 | -830.8 | -315.9 | |||||
Levered Free Cash Flow Margin | -1.11K | -435.05 | -802.02 | -462.84 | -320.53 | |||||
Unlevered Free Cash Flow Margin | -979.5 | -331.57 | -640.01 | -244.08 | -241.47 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | |||||
Fixed Assets Turnover | 0.67 | 0.92 | 0.91 | 1.14 | 3.56 | |||||
Receivables Turnover (Average Receivables) | 5.57 | 4.83 | 3.33 | 2.88 | 2.19 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.57 | 1.36 | 1.95 | 1.18 | 1.99 | |||||
Quick Ratio | 1.5 | 1.25 | 1.85 | 1.14 | 1.72 | |||||
Operating Cash Flow to Current Liabilities | -1.13 | -1.28 | -1.51 | -0.66 | -0.49 | |||||
Days Sales Outstanding (Average Receivables) | 65.55 | 75.49 | 109.49 | 127.06 | 166.88 | |||||
Average Days Payable Outstanding | 94.88 | 122.52 | 143.63 | 121.26 | - | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 18.14 | 21.51 | 23.21 | 24.76 | 21.45 | |||||
Total Debt / Total Capital | 15.36 | 17.7 | 18.84 | 19.84 | 17.66 | |||||
LT Debt/Equity | 8.52 | 19.86 | 21.22 | 21.32 | 11.94 | |||||
Long-Term Debt / Total Capital | 7.21 | 16.34 | 17.22 | 17.09 | 9.83 | |||||
Total Liabilities / Total Assets | 21.93 | 24.93 | 25.03 | 28.21 | 23.86 | |||||
EBIT / Interest Expense | -6.84 | -4.77 | -3.56 | -2.81 | -2.87 | |||||
EBITDA / Interest Expense | -6.58 | -4.51 | -3.35 | -2.58 | -2.58 | |||||
(EBITDA - Capex) / Interest Expense | -6.68 | -4.52 | -3.37 | -2.59 | -2.61 | |||||
Total Debt / EBITDA | -1.01 | -1.4 | -1.79 | -2.23 | -2.29 | |||||
Net Debt / EBITDA | 0.3 | -0.61 | -0.69 | -1.05 | 0.6 | |||||
Total Debt / (EBITDA - Capex) | -0.99 | -1.4 | -1.78 | -2.22 | -2.26 | |||||
Net Debt / (EBITDA - Capex) | 0.29 | -0.61 | -0.69 | -1.04 | 0.59 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -76.81 | 37.36 | -26.54 | -21.32 | 191.39 | |||||
Gross Profit, 1 Yr. Growth % | 58.64 | -31.85 | -11.13 | -25.84 | -32.75 | |||||
EBITDA, 1 Yr. Growth % | 46.47 | -26.86 | -14.21 | -16.11 | 3.75 | |||||
EBITA, 1 Yr. Growth % | 46.68 | -26.49 | -14.24 | -16.68 | 3.54 | |||||
EBIT, 1 Yr. Growth % | 45.68 | -26.14 | -14.01 | -16.33 | 7.71 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 26.78 | -7.55 | -10.35 | 7.41 | 16.13 | |||||
Net Income, 1 Yr. Growth % | 26.78 | -7.55 | -10.35 | 7.41 | 16.13 | |||||
Normalized Net Income, 1 Yr. Growth % | 33.34 | -21.82 | -1.68 | -13.74 | 10.8 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 10.79 | -13.78 | -21.3 | -15.34 | -5.09 | |||||
Accounts Receivable, 1 Yr. Growth % | 194.99 | 11.2 | 2.34 | -34.16 | 766.56 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 18.2 | -17.92 | -34.86 | -40.87 | 51.72 | |||||
Total Assets, 1 Yr. Growth % | 1.52 | -11.09 | 1.1 | -0.04 | 17.27 | |||||
Tangible Book Value, 1 Yr. Growth % | -102.64 | -9.69K | -7.67 | 26.59 | -126.86 | |||||
Common Equity, 1 Yr. Growth % | 5.84 | -14.51 | 0.96 | -4.28 | 24.38 | |||||
Cash From Operations, 1 Yr. Growth % | 89.27 | -34.71 | -3.82 | -23.41 | 3.09 | |||||
Capital Expenditures, 1 Yr. Growth % | -21.42 | -90.47 | 68.15 | 2.65 | 150.92 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | 352.8 | -46.48 | 35.42 | -54.59 | 101.8 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | 699.8 | -53.65 | 41.79 | -69.99 | 188.29 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -33.23 | -43.65 | 0.45 | -23.97 | 51.42 | |||||
Gross Profit, 2 Yr. CAGR % | 15.72 | 3.99 | -22.18 | -18.82 | -29.16 | |||||
EBITDA, 2 Yr. CAGR % | 16.8 | 3.51 | -20.79 | -15.16 | -6.7 | |||||
EBITA, 2 Yr. CAGR % | 16.94 | 3.85 | -20.6 | -15.47 | -7.12 | |||||
EBIT, 2 Yr. CAGR % | 16.62 | 3.74 | -20.31 | -15.18 | -5.07 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 4.9 | 8.26 | -8.96 | -1.87 | 11.68 | |||||
Net Income, 2 Yr. CAGR % | 4.9 | 8.26 | -8.96 | -1.87 | 11.68 | |||||
Normalized Net Income, 2 Yr. CAGR % | 13.1 | 2.1 | -12.33 | -7.9 | -2.24 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -5.18 | -2.26 | -17.63 | -18.38 | -10.37 | |||||
Accounts Receivable, 2 Yr. CAGR % | 7.24 | 81.11 | 6.68 | -14.47 | 138.87 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 283.37 | -1.5 | -26.88 | -37.94 | -5.29 | |||||
Total Assets, 2 Yr. CAGR % | 6.86 | -5 | -5.19 | 0.53 | 8.27 | |||||
Tangible Book Value, 2 Yr. CAGR % | -90.87 | 59.01 | 840.94 | 8.11 | -41.69 | |||||
Common Equity, 2 Yr. CAGR % | 9.94 | -4.88 | -7.09 | -1.69 | 9.11 | |||||
Cash From Operations, 2 Yr. CAGR % | 35.87 | 8.03 | -20.75 | -14.17 | -11.14 | |||||
Capital Expenditures, 2 Yr. CAGR % | 142.97 | -72.63 | -59.96 | 31.38 | 60.49 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 245.81 | 55.68 | -14.87 | -21.45 | -4.28 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 126.34 | 92.56 | -18.93 | -34.62 | -6.99 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -24.52 | -15.16 | -38.44 | -7.4 | 18.98 | |||||
Gross Profit, 3 Yr. CAGR % | 13.11 | -2.99 | -1.31 | -23.42 | -24.75 | |||||
EBITDA, 3 Yr. CAGR % | 13.83 | -0.06 | -2.77 | -19.26 | -9.27 | |||||
EBITA, 3 Yr. CAGR % | 13.72 | 0.18 | -2.57 | -19.31 | -9.56 | |||||
EBIT, 3 Yr. CAGR % | 13.37 | 0.15 | -2.55 | -19 | -8.15 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 40.95 | 0.57 | 1.66 | -3.8 | 3.79 | |||||
Net Income, 3 Yr. CAGR % | 40.95 | 0.57 | 1.66 | -3.8 | 3.79 | |||||
Normalized Net Income, 3 Yr. CAGR % | 15.64 | 0 | 0.82 | -12.8 | -2.05 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 29.15 | -8.14 | -9.07 | -18.27 | -14.17 | |||||
Accounts Receivable, 3 Yr. CAGR % | -32.93 | 8.55 | 49.73 | -6.65 | 85.08 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 123.73 | 129.35 | -14.18 | -31.88 | -16.4 | |||||
Total Assets, 3 Yr. CAGR % | 2.46 | 0.51 | -3.01 | -3.5 | 5.82 | |||||
Tangible Book Value, 3 Yr. CAGR % | -71.96 | -7.19 | 32.66 | 382.14 | -32.04 | |||||
Common Equity, 3 Yr. CAGR % | 2.12 | 1.1 | -2.97 | -6.17 | 6.32 | |||||
Cash From Operations, 3 Yr. CAGR % | 12.46 | 4.41 | 3.93 | -21.65 | -8.77 | |||||
Capital Expenditures, 3 Yr. CAGR % | 101.6 | -17.44 | -49.87 | -45.2 | 63.01 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -5.2 | 85.67 | 48.61 | -30.96 | 7.58 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -8.79 | 33.42 | 73.88 | -41.79 | 7.21 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -29.41 | 33.46 | -15.43 | -18.8 | -11.76 | |||||
Gross Profit, 5 Yr. CAGR % | 43.68 | 40.77 | -2.6 | -9.66 | -14.35 | |||||
EBITDA, 5 Yr. CAGR % | 14.68 | -2.18 | -1.53 | -6.4 | -4.36 | |||||
EBITA, 5 Yr. CAGR % | 14.21 | -2.25 | -1.5 | -6.4 | -4.42 | |||||
EBIT, 5 Yr. CAGR % | 14.31 | -2.2 | -1.53 | -6.29 | -3.57 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 88.73 | 3.53 | 18.34 | -0.41 | 5.56 | |||||
Net Income, 5 Yr. CAGR % | 88.73 | 3.53 | 18.34 | -0.41 | 5.56 | |||||
Normalized Net Income, 5 Yr. CAGR % | 15.72 | 0.53 | 3.52 | -3.24 | -0.41 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 70.19 | -6.24 | 7.89 | -13.27 | -10.51 | |||||
Accounts Receivable, 5 Yr. CAGR % | 34.17 | 36.23 | -19.25 | -1.32 | 83.48 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 31.71 | 40.59 | 43.04 | 35.96 | -10.73 | |||||
Total Assets, 5 Yr. CAGR % | 1.71 | 0.2 | -0.67 | 0.52 | 1.36 | |||||
Tangible Book Value, 5 Yr. CAGR % | -57.26 | 3.24 | 14.31 | -1.35 | -4.52 | |||||
Common Equity, 5 Yr. CAGR % | 1.94 | -0.78 | -1.67 | -0.03 | 1.69 | |||||
Cash From Operations, 5 Yr. CAGR % | 3.93 | -7.18 | -3.35 | -3.46 | -2.39 | |||||
Capital Expenditures, 5 Yr. CAGR % | 17.93 | -12.78 | 5.6 | -0.58 | -20.16 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 12.83 | -2.71 | -9.19 | 31.53 | 24.64 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 9.98 | -7.85 | -12.99 | 0.21 | 35.38 |
- Stock Market
- Equities
- MSB Stock
- Financials Mesoblast Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















